Compare WAVE & FEMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WAVE | FEMY |
|---|---|---|
| Founded | 2011 | 2004 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Medical/Dental Instruments |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 29.4M | 25.6M |
| IPO Year | 2021 | 2021 |
| Metric | WAVE | FEMY |
|---|---|---|
| Price | $6.89 | $0.37 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $5.50 |
| AVG Volume (30 Days) | 10.8K | ★ 348.2K |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 44.71 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,293,313.00 |
| Revenue This Year | $436.84 | $105.16 |
| Revenue Next Year | N/A | $200.23 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 40.77 |
| 52 Week Low | $4.52 | $0.31 |
| 52 Week High | $9.85 | $1.22 |
| Indicator | WAVE | FEMY |
|---|---|---|
| Relative Strength Index (RSI) | 58.60 | 35.04 |
| Support Level | $6.72 | $0.37 |
| Resistance Level | $7.10 | $0.44 |
| Average True Range (ATR) | 0.45 | 0.03 |
| MACD | 0.02 | 0.00 |
| Stochastic Oscillator | 54.04 | 24.07 |
Eco Wave Power Global AB is a Sweden-based wave energy company engaged in the development of a smart and cost-efficient WEC, technology that converts ocean and sea waves into clean electricity. Its WEC technology employs units of point absorber floating devices, referred to as floaters, which are installed on existing marine structures such as piers, breakwaters, and jetties, or in locations in which such marine structures are required. Geographical presence in Israel, USA and Mexico.
Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.